跳至主要内容
临床试验/IRCT20200913048708N1
IRCT20200913048708N1尚未招募2 期

Evaluation of efficacy and safety of adding Chlorpromazine to Atazanavir/Ritonavir regimen in the treatment of COVID-19 patients, a randomized double-blind clinical trial

Mazandaran University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • all admitted patients with covid -19 infection based on clinical findings ,PCR or lung CT abnormality consistent with covid-19
  • spo2 bellow 93 mmHg
  • age above 18 years old

排除标准

  • patient rejection
  • history of antipsycotic use
  • history of seizure, dementia and parkinson disease
  • Hx of liver disease
  • Hx of feochromocytoma
  • allergy to phenothiazines drug
  • any drug interaction between patients medicines and chlorpromazine
  • pregnancy and lactation
  • Hx of covid treatments
  • bradycardia < 60 /min
  • multi-organ failure

研究者

相似试验